Monopar Therapeutics (MNPR) Tops Q1 EPS by 38c

Monopar Therapeutics (NASDAQ: MNPR) reported Q1 EPS of $0.38.

For earnings history and earnings-related data on Monopar Therapeutics (MNPR) click here.

You May Also Be Interested In

• Franklin BSP Realty Trust (FBRT) Reiterated at Market Outperform by Citizens on Q1 Results
• Jefferies Downgrades Huntington Bancshares (HBAN) to Hold
• TD Cowen Upgrades Flagstar Bank (FLG) to Buy